Sabine BrookmanMay - Aura Biosciences Senior Oncology
| AURA Stock | USD 8.96 0.08 0.90% |
Executive
Sabine BrookmanMay is Senior Oncology of Aura Biosciences
| Address | 80 Guest Street, Boston, MA, United States, 02135 |
| Phone | 617 500 8864 |
| Web | https://www.aurabiosciences.com |
Aura Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5099) %, meaning that it created substantial loss on money invested by shareholders. Aura Biosciences' management efficiency ratios could be used to measure how well Aura Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Aura Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.3 M, whereas Total Assets are forecasted to decline to about 153.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Asim Siddiqui | Seer Inc | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Leonard MD | C4 Therapeutics | 62 | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Mike Campbell | Opthea | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| JD Esq | Seer Inc | 55 | |
| Fang Li | Opthea | 60 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Martin Goldberg | Seer Inc | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Thomas Reilly | Opthea | 52 | |
| Michael Chang | Alx Oncology Holdings | N/A | |
| Xiaohong She | Adagene | 57 | |
| Christian CPA | Bioatla | 48 | |
| Cedrik MD | Immatics NV | 48 | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.3 |
Aura Biosciences Leadership Team
Elected by the shareholders, the Aura Biosciences' board of directors comprises two types of representatives: Aura Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aura. The board's role is to monitor Aura Biosciences' management team and ensure that shareholders' interests are well served. Aura Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aura Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Mountfield, Senior Quality | ||
| Patrick Nealon, Senior Operations | ||
| CPE MBA, Chief RD | ||
| Jill MD, Chief Development | ||
| Amy Elazzouzi, Interim Officer | ||
| Paulo Carvalho, VP Operations | ||
| Bruce MD, Senior Oncology | ||
| Conor Kilroy, General Secretary | ||
| Julie Feder, Secretary CFO | ||
| Elisabet Pinos, CEO, Founder | ||
| Mark Rosch, Chief Officer | ||
| Michele MBA, VP Chain | ||
| Anthony MD, Therapeutic Oncology | ||
| Joseph Lyons, VP HR | ||
| Mark DVM, Chief Officer | ||
| Sabine BrookmanMay, Senior Oncology |
Aura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aura Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 288.28 M | ||||
| Shares Outstanding | 49.95 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 74.06 % | ||||
| Number Of Shares Shorted | 1.13 M | ||||
| Price To Book | 2.54 X | ||||
| EBITDA | (83.7 M) | ||||
| Net Income | (76.41 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Return On Assets (0.30) | Return On Equity (0.51) |
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.